1. Home
  2. CLB vs CTMX Comparison

CLB vs CTMX Comparison

Compare CLB & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core Laboratories Inc.

CLB

Core Laboratories Inc.

N/A

Current Price

$12.47

Market Cap

864.2M

Sector

N/A

ML Signal

N/A

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

N/A

Current Price

$3.65

Market Cap

716.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CLB
CTMX
Founded
1936
2008
Country
United States
United States
Employees
3300
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
864.2M
716.9M
IPO Year
2023
2015

Fundamental Metrics

Financial Performance
Metric
CLB
CTMX
Price
$12.47
$3.65
Analyst Decision
Hold
Strong Buy
Analyst Count
2
10
Target Price
$12.50
$12.10
AVG Volume (30 Days)
420.1K
2.9M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
0.23%
N/A
EPS Growth
N/A
N/A
EPS
0.11
N/A
Revenue
$526,520,000.00
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.75
$7.61
P/E Ratio
$114.00
$22.58
Revenue Growth
0.51
N/A
52 Week Low
$9.79
$1.90
52 Week High
$20.36
$8.21

Technical Indicators

Market Signals
Indicator
CLB
CTMX
Relative Strength Index (RSI) 61.67 57.65
Support Level $11.75 $3.43
Resistance Level $12.86 $3.96
Average True Range (ATR) 0.45 0.20
MACD 0.02 0.04
Stochastic Oscillator 84.90 67.83

Price Performance

Historical Comparison
CLB
CTMX

About CLB Core Laboratories Inc.

Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: